Synlogic, Inc. (SYBX) Financial Ratios
13 years of historical data (2013–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
0.62
↓-33% vs avg
5yr avg: 0.93
30Y Low0.4·High9.3
ROE
↑
-8.2%
↓+86% vs avg
5yr avg: -57.5%
30Y Low-135%·High-8%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
SYBX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Synlogic, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $7M | $14M | $17M | $25M | $54M | $134M | $77M | $78M | $167M | $65M | $562M |
| Enterprise Value | $-7648649 | $-878662 | $-1785307 | $18M | $59M | $138M | $68M | $77M | $157M | $-20936422 | $547M |
| P/E Ratio → | -7.50 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | 2134.34 | 7.43 | 46.16 | 76.30 | 141.94 | 35.11 | 66.40 | 26.68 | 1266.33 |
| P/B Ratio | 0.62 | 1.16 | 1.34 | 0.59 | 0.66 | 0.91 | 0.67 | 0.50 | 1.35 | 0.77 | 9.32 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
SYBX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | -223.16 | 5.44 | 49.92 | 78.67 | 124.14 | 34.59 | 62.13 | -8.57 | 1231.69 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
SYBX Profitability
Margins and return-on-capital ratios measuring operating efficiency
Operating margins have compressed from -1636.3% to -511875.0% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -8.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -491.2% | 100.0% | 64.2% |
| Operating Margin | — | — | -511875.0% | -1636.3% | -5713.5% | -3464.4% | -11094.7% | -2446.4% | -2032.9% | -1670.4% | -5995.0% |
| Net Profit Margin | — | — | -291987.5% | -1699.3% | -5605.7% | -3452.7% | -10857.4% | -2309.9% | -1922.0% | -1652.1% | -5916.2% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -8.2% | -8.2% | -84.3% | -91.5% | -57.6% | -46.2% | -43.5% | -36.6% | -46.3% | -55.5% | -36.1% |
| ROA | -5.7% | -5.7% | -49.0% | -61.5% | -46.3% | -38.0% | -35.6% | -31.2% | -40.4% | -49.3% | -33.9% |
| ROIC | — | — | -205.7% | -67.3% | -42.4% | -35.5% | -34.7% | -30.3% | -68.5% | -139.6% | -99.1% |
| ROCE | -32.6% | -32.6% | -120.6% | -71.7% | -51.2% | -40.5% | -38.4% | -34.9% | -46.0% | -53.7% | -36.4% |
SYBX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $15M exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | 0.40 | 0.25 | 0.14 | 0.20 | 0.16 | 0.00 | 0.01 | 0.02 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.24 | -1.48 | -0.16 | 0.05 | 0.03 | -0.08 | -0.01 | -0.09 | -1.01 | -0.25 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | -57267.00 | -33072.50 | -30279.50 | -9861.17 | -2445.33 | -1125.40 | -707.37 | — |
Net cash position: cash ($15M) exceeds total debt ($0)
SYBX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Synlogic, Inc.'s current ratio of 4.30x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 2.45x to 4.30x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.30 | 4.30 | 2.80 | 2.45 | 6.58 | 13.23 | 12.87 | 15.03 | 14.71 | 9.64 | 22.23 |
| Quick Ratio | 4.30 | 4.30 | 2.80 | 2.45 | 6.58 | 13.23 | 12.87 | 15.03 | 14.71 | 9.64 | 22.23 |
| Cash Ratio | 4.09 | 4.09 | 2.67 | 2.34 | 6.40 | 12.76 | 12.10 | 13.49 | 14.71 | 9.64 | 21.91 |
| Asset Turnover | — | — | 0.00 | 0.04 | 0.01 | 0.01 | 0.00 | 0.01 | 0.02 | 0.02 | 0.01 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
SYBX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Synlogic, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 4.6% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 4.6% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $12M | $12M | $7M | $5M | $4M | $2M | $2M | $2M | $448309 | $3M |
Peer Comparison
Compare SYBX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 SYBXYou | $7M | -7.5 | — | — | — | — | -8.2% | — | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 ACMR | $4B | 43.2 | 27.5 | — | 44.4% | 12.1% | 6.2% | 7.0% | 2.4 |
 AGEN | $132M | -1102.9 | — | — | 90.3% | -18.0% | — | — | — |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 MIRM | $5B | -219.0 | 2461.9 | 94.2 | 80.7% | -4.2% | -8.6% | -5.0% | 151.5 |
 ARWR | $11B | -6389.3 | 90.4 | 69.6 | 97.1% | 11.9% | -0.5% | 9.3% | 3.0 |
 RCKT | $398M | -1.8 | — | — | — | — | -60.3% | -63.2% | — |
 ILMN | $21B | 25.5 | 19.6 | 22.6 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 TMO | $176B | 26.8 | 19.0 | 28.0 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
 CRSP | $5B | -8.1 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 13 years · Updated daily
See SYBX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SYBX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SYBX vs IMVT
Side-by-side business, growth, and profitability comparison vs Immunovant, Inc..
Start ComparisonSYBX — Frequently Asked Questions
Quick answers to the most common questions about buying SYBX stock.
What is Synlogic, Inc.'s P/E ratio?
Synlogic, Inc.'s current P/E ratio is -7.5x. This places it at the 50th percentile of its historical range.
What is Synlogic, Inc.'s ROE?
Synlogic, Inc.'s return on equity (ROE) is -8.2%. The historical average is -58.2%.
Is SYBX stock overvalued?
Based on historical data, Synlogic, Inc. is trading at a P/E of -7.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.